VOR Vor Biopharma Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817229 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY155.3%
TTM EPS YoY177.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA402.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets127.6%
Debt / equity—
Current ratio13.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.09x
Accruals ratio438.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $321.53M | $93.31M | $94.31M | $64.55M | $47.53M |
| SG&A expense | $50.11M | $27.88M | $31.72M | $28.87M | $21.49M |
| Operating income | -$371.64M | -$121.19M | -$126.04M | -$93.42M | -$69.02M |
| Net income | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -$68.90M |
| EBITDA | -$368.75M | -$117.66M | -$122.54M | -$90.89M | -$67.58M |
| EPS (basic) | -70.50 | -34.03 | -1.75 | -2.33 | -2.10 |
| EPS (diluted) | -70.50 | -34.03 | -1.75 | -2.33 | -2.10 |
| Weighted avg. shares (diluted) | 9.87M | 3.44M | 67.19M | 39.55M | 33.43M |
| Balance sheet | |||||
| Cash & equivalents | $396.49M | $81.95M | $31.36M | $57.71M | $119.80M |
| Short-term investments | $58.72M | $9.98M | $105.81M | $172.54M | $87.67M |
| Current assets | $458.11M | $96.51M | $140.80M | $236.95M | $214.40M |
| PP&E, net | $533,000 | $6.58M | $10.05M | $12.63M | $6.85M |
| Total assets | $464.13M | $142.89M | $198.13M | $299.37M | $242.59M |
| Current liabilities | $25.17M | $18.61M | $15.57M | $13.12M | $10.15M |
| Total liabilities | $628.44M | $46.23M | $47.40M | $48.76M | $26.33M |
| Shareholders' equity | -$164.31M | $96.66M | $150.72M | $250.61M | $216.26M |
| Shares outstanding | 38.72M | 6.24M | 67.89M | 66.00M | 37.17M |
| Cash flow statement | |||||
| Operating cash flow | -$142.71M | -$99.66M | -$100.29M | -$85.14M | -$69.14M |
| Capital expenditure | $941,000 | $229,000 | $1.07M | $8.46M | $3.89M |
| Free cash flow | -$143.65M | -$99.89M | -$101.36M | -$93.61M | -$73.04M |
| Investing cash flow | -$48.80M | $96.86M | $71.01M | -$94.09M | -$91.65M |
| Financing cash flow | $503.81M | $53.39M | $2.94M | $117.14M | $232.91M |
| Depreciation & amortization | $2.89M | $3.53M | $3.49M | $2.52M | $1.43M |
| Stock-based compensation | $18.91M | $9.85M | $13.36M | $10.70M | $4.32M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.